E-LIB Suche - Ergebnisse für: Nagai, Sumimasa

1

Characteristics of Drugs from Non‐Global Companies for Hema..:

Matsuda, Kensuke ; Nagai, Sumimasa ; Sugimoto, Koichi
Clinical Pharmacology & Therapeutics. , 2024

2

Drug approval delays in hematologic malignancies between Eu..:

Matsuda, Kensuke ; Nagai, Sumimasa ; Sugimoto, Koichi
Japanese Journal of Clinical Oncology. 53 (2023) 12 - p. 1125-1129 , 2023

Link: https://doi.org/10.1093/..

3

Recommendations related to the analytical equivalence asses..:

Nagai, Sumimasa ; Nishihara, Hiroshi ; Suzuki, Takayoshi...
Cancer Science. 113 (2022) 10 - p. 3282-3290 , 2022

Link: https://doi.org/10.1111/..

4

Biosimilar Epoetin in the United States: A View from the So..:

, In: Cancer Treatment and Research; Cancer Drug Safety and Public Health Policy,

Nagai, Sumimasa ; Witherspoon, Bartlett ; Nabhan, Chadi. - p. 41-51 , 2022

Link: https://doi.org/10.1007/..

5

Tumor mutational burden measurement using comprehensive gen..:

Kage, Hidenori ; Kohsaka, Shinji ; Tatsuno, Kenji...
Japanese Journal of Clinical Oncology. 52 (2022) 8 - p. 925-929 , 2022

Link: https://doi.org/10.1093/..

6

The First 2 Years of Biosimilar Epoetin for Cancer and Chem..:

Bennett, Charles L. ; Nagai, Sumimasa ; Bennett, Andrew C....
The Oncologist. 26 (2021) 8 - p. e1418-e1426 , 2021

Link: https://doi.org/10.1002/..

7

Addressing the dichotomy between individual and societal ap..:

Salgado, Roberto ; Solit, David B. ; Rimm, David L....
European Journal of Cancer. 114 (2019) - p. 128-136 , 2019

Link: https://doi.org/10.1016/..

8

Current Trends in Clinical Development of Gene and Cellular..:

Nagai, Sumimasa ; Sugiyama, Daisuke
Clinical Therapeutics. 41 (2019) 1 - p. 174-184.e3 , 2019

Link: https://doi.org/10.1016/..

9

Flexible and Expedited Regulatory Review Processes for Inno..:

Nagai, Sumimasa
International Journal of Molecular Sciences. 20 (2019) 15 - p. 3801 , 2019

Link: https://doi.org/10.3390/..

10

Regulatory and Clinical Experiences with Biosimilar Filgras..:

Chen, Brian ; Nagai, Sumimasa ; Armitage, James O....
The Oncologist. 24 (2019) 4 - p. 537-548 , 2019

Link: https://doi.org/10.1634/..

11

Global Development of Anticancer Therapies for Rare Cancers..:

Lyerly, H. Kim ; Ren, Jun ; Canetta, Renzo...
Journal of Global Oncology. , 2018

Link: https://doi.org/10.1200/..

12

Drug approval based on randomized phase 3 trials for relaps..:

Nagai, Sumimasa ; Ozawa, Keiya
Investigational New Drugs. 36 (2018) 3 - p. 487-495 , 2018

Link: https://doi.org/10.1007/..

13

Societal challenges of precision medicine: Bringing order t..:

Salgado, Roberto ; Moore, Helen ; Martens, John W.M....
European Journal of Cancer. 84 (2017) - p. 325-334 , 2017

Link: https://doi.org/10.1016/..

14

Regulatory approval pathways for anticancer drugs in Japan,..:

Nagai, Sumimasa ; Ozawa, Keiya
International Journal of Hematology. 104 (2016) 1 - p. 73-84 , 2016

Link: https://doi.org/10.1007/..

15

Evolving Japanese regulations on companion diagnostics:

Nagai, Sumimasa ; Urata, Masaaki ; Sato, Hiroyuki...
Nature Biotechnology. 34 (2016) 2 - p. 141-144 , 2016

Link: https://doi.org/10.1038/..